Close
The European Commission has selected Dicot to compete in the Innovation Radar Prize

Uppsala, September 7, 2022. The European Commission has selected Dicot from thousands of small and medium-sized European companies as one of the companies to participate in the Innovation Radar Prize 2022.

Dicot's goal is to drastically change the way of treating erectile dysfunction by developing a new modern potency drug. The company has been noticed by the European Commission, which recently contacted and invited the company to participate in the Innovation Radar Prize 2022. Dicot is thus one of the companies selected in competition with thousands of EU-funded small and medium-sized enterprises.

The Innovation Radar is the European Commission's initiative to highlight EU-funded research and innovation projects with high potential. The goal is to make it easier for citizens, public officials, investors and corporates to identify successful businesses that have been supported by the EU. The companies are thereby given the opportunity to follow in the footsteps of previously funded companies, such as Skype, TomTom and BioNTech.

Within the framework of the initiative, the annual Innovation Radar Prize has been awarded since 2015, where the winners, among other things, get extensive exposure to European investors. The jury consists of renowned entrepreneurs, investors and start-up accelerators.

"It is very encouraging that we have been asked to participate in this competition. In addition to the honour, it is a welcome element in our work to establish Dicot internationally and get attention for what we do", says Elin Trampe, CEO of Dicot.

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.

2022-09-07

Uppsala, September 7, 2022. The European Commission has selected Dicot from thousands of small and medium-sized European companies as one of the companies to participate in the Innovation Radar Prize 2022.

2022-08-25
Regulatory

Press release: Uppsala, August 25, 2022. A summary of the Interim report January - June 2022, for Dicot AB (publ) is now available on the company website www.dicot.se.

2022-06-29
Regulatory

Press release: Uppsala, June 29, 2022. Dicot AB is developing a new potency drug aiming at becoming the first choice of treatment. The company announces today that the newly developed oral formulation demonstrates good results in a recently conducted efficacy study.

2022-06-17
Regulatory

Press release: Uppsala, June 17, 2022.

Dicot AB (publ) ("Dicot" or the "Company") announces the outcome regarding exercising of warrants of series TO 3. Holders of warrants exercised 34,202,814 warrants, corresponding to approximately 90 percent of the number of outstanding warrants, for subscription of 34,202,814 shares at a subscription price of SEK 0.29 per share. Through the exercise of the warrants, Dicot will receive approximately SEK 10 million before issue costs.

2022-06-13
Regulatory

Press release: Uppsala, June 13, 2022. The company announces that members in the board and management are increasing their shareholding in the company.

2022-06-13

Today, June 13, 2022, is the last day of trading with the warrants of series TO 3. The subscription period for the warrants of series TO 3 will continue up until June 15, 2022.

2022-06-10

Press release: Uppsala, June 10, 2022. Dicot AB is developing the drug candidate LIB-01, a potency drug to better treat erectile dysfunction and premature ejaculation. The company announces that it is now moving forward with a new patent application in order to extend the patent protection around the company's drug candidate until at least 2042.

2022-06-09

Uppsala, June 9, 2022. Meet Dicot's CEO Elin Trampe at Småbolagsdagarna on Monday June 13 when she presents the company's development of a new potency drug and the latest advances. Among other things, she will talk about a newly started project with Uppsala University and raise the issue of the culture of silence among men with erectile dysfunction.

2022-06-01

Today on June 1, 2022, the subscription period for the warrants of series TO 3 issued in connection with the rights issue of units in Dicot AB (publ) during the fourth quarter of 2021. The subscription period lasts until June 15, 2022.

2022-05-31

Uppsala, May 31, 2022. Dicot AB is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. Dicot announces today that the company has entered a research collaboration with Uppsala University and the W. Szafer Institute of Botany of the Polish Academy of Sciences (PAS) to investigate a new technology to make starting material for production of the drug substance.

1
2
...
17
>>